Association Between P2Y12 Inhibitor Reloading and In-Hospital Outcomes for Patients with Non-St-segment Elevation Acute Coronary Syndrome Already on Chronic P2Y12 Receptor Inhibitors Therapy in China: Findings from the CCC-ACS (improving Care for Cardiovascular Disease in China-acute Coronary Syndrome) Project
Yintang Wang,Yu Geng,Ou Zhang,Qin Xu,Yajun Xue,Boda Zhou,Ping Zhang,Aihua Li,Bao Li,Biao Xu,Guangshu Han,Bin Li,Bin Liu,Bin Wang,Bing Fu,Bo Yu,Bosong Yang,Caidong Luo,Changqian Wang,Changyong Liu,Chuanliang Liang,Chuanyu Gao,Chunlin Lai,Chuntong Wang,Chunyan Zhang,Chunyang Wu,Congliang Zhang,Cui Bin,Lan Huang,Daoquan Peng,Dawen Xu,Di Wu,Dongmei Zhu,Dongsheng Chai,Dongyan Li,Fakuan Tang,Jun Xiao,Fang Zhao,Fangfang Huang,Fanju Meng,Fengwei Li,Fudong Gan,Gang Xu,Gengsheng Sang,Genshan Ma,Guixia Zhang,Guizhou Tao,Guo Li,Guoduo Chen,Guoqin Xin,Guoqing Li,Guosheng Fu,Guoxiong Chen,Hailong Lin,Haiping Guo,Haiyun Lin,Hong Jiang,Hong Liu,Hong Luan,Hong Zhang,Honghua Deng,Hongwei Li,Honhju Wang,Hualing Liu,Hui Dong,Hui Liu,Huifang Zhang,Huifeng Wang,Huimin Chu,Jiabin Xi,Jian Yang,Jianfeng Ye,Jianhao Li,Jianhong Tao,Jianwen Liu,JiaoMei Yang,Jiawang Ding,Jiayi Tong,Jie Chen,Jie Jiang,Jie Yang,Jifu Li,Jinchuan Yan,Jing Hu,Jing Xu,Jingfeng Wang,Jinglan Diao,Jingshan Zhao,Jinru Wei,Jinxing Yi,Jinzi Su,Jiong Tang,Jiyan Chen,Jiyan Yin,Juexin Fan,Jun Guan,Junbo Ge,Junming Liu,Junping Deng,Junping Fang,Junxia Li,Kaihong Chen,Kalan Luo,Keng Wu,Lang Ji,Lang Li,Li Jiang,Li Wei,Lijun Meng,Likun Ma,Lilong Tang,Lin Wang,Lin Wei,Ling Li,Ling Tao,Liqiong Yang,Lirong Wu,Man Zhang,Kaiming Chen,Meisheng Lai,Miao Tian,Mingcheng Bai,Minghua Han,Moshui Chen,Naiyi Liang,Nan Jia,Peiying Zhang,Peng Qu,Pengfei Zhang,Ping Chen,Ping Hou,Ping Xie,Pingshuan Dong,Qiang Wu,Qiang Xie,Qiaoqing Zhong,Qichun Wang,Qinfeng Su,Rong Chang,Rong Lin,Ruiping Zhao,Shaobin Jia,Shaoping Nie,Shaowu Ye,Shenghu He,Shengyong Chen,Shixin Ma,Shuangbin Li,Shuanli Xin,Shudong Xia,Shuhua Zhang,Shuqiu Qu,Shuren Ma,Siding Wang,Songbai Li,Suxin Luo,Tao Liu,Tao Zhang,Tian Tuo,Tianchang Li,Tianlun Yang,Tianmin Du,Tongguo Wu,Wei Liu,Wei Mao,Wei Tuo,Wei Wang,Weihong Jiang,Weijian Huang,Weijun Liu,Weiqing Fan,Weiting Xu,Wenhua Lin,Xi Su,Xia Chen,Xianan Zhang,Xianghua Fu,Xiangjun Yang,Xianxian Zhao,Xiaochuan Ma,Xiaofei Sun,Xiaojun Wang,Xiaolan Li,Xiaolei Li,Xiaoli Yang,Xiaoping Chen,Xiaoqin Zhang,Xiaoshu Cheng,Xiaowei Peng,Xiaowen Ma,Xiaoyong Qi,Xiaoyun Feng,Ximing Chen,Xin Tang,Xingsheng Tang,Xingsheng Zhao,Xiufeng Chen,Xudong Li,Xue Li,Xuebo Liu,Xuemei Peng,Yaling Han,Yan Wang,Yanbo Niu,Yang Yu,Yang Zheng,Yanli Wang,Yanlie Zheng,Yansong Guo,Yanzong Yang,Yi Huang,Yin Liu,Ying Guo,Yingchao Luo,Yinglu Hao,Yingxian Sun,Yingzhong Lin,Yitong Ma,Yong Guo,Yong Li,Yongdong Li,Yonglin Zhang,Yuanzhe Jin,Yue Li,Yuehua Huang,Yuemin Sun,Yuheng Yang,Yuhua Zhu,Yuhuan Shi,Yulan Zhao,Yuqing Hou,Zeqi Zheng,Zesheng Xu,Zewei Ouyang,Zeyuan He,Zhan Lv,Zhanquan Li,Zhaofa He,Zheng Ji,Zheng Zhang,Zhenguo Ji,Zhenqi Su,Zhenyu Yang,Zhihong Ou,Zhijian Yang,Zhiming Yang,Zhirong Wang,Zhiyuan Song,Zhongshan Wang,Zuyi Yuan
DOI: https://doi.org/10.1186/s40001-023-01025-6
IF: 4.981
2023-01-01
European Journal of Medical Research
Abstract:Background The association between P2Y12 receptor inhibitors reloading and in-hospital outcomes in non-ST-segment elevation acute coronary syndrome (NSTEACS) patients who were on chronic P2Y12 receptor inhibitors therapy remained underdetermined.Methods The Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome (CCC-ACS project) is a national registry active from November 2014 to December 2019. 4790 NSTEACS patients on chronic P2Y12 receptor inhibitors therapy were included. Cox proportional hazard models, Kaplan-Meier curves, and subgroup analyses were conducted.Results The NSTEACS patients who received reloading of P2Y12 receptor inhibitors were younger and had fewer comorbid conditions. The reloading group had a lower risk of major adverse cardiac events (MACE) (0.51% vs. 1.43%, P = 0.007), and all-cause death (0.36% vs. 0.99%, P = 0.028), the risks of myocardial infarction and major bleeding were not significantly different between patients with and without reloading. In survival analysis, a lower cumulative risk of MACE could be identified (Log-rank test, P = 0.007) in reloading group. In the unadjusted Cox model, reloading P2Y12 receptor inhibitors was associated with a decreased risk of MACE [HR, 0.35; 95% CI 0.16-0.78; (P = 0.010)] and all-cause death [HR, 0.37; 95% CI 0.14-0.94; (P = 0.036)]. Reloading of P2Y12 receptor inhibitors was associated with a decreased risk of MACE in most of the subgroups.Conclusions In NSTEACS patients already taking P2Y12 receptor inhibitors, we observed a decreased risk of in-hospital MACEs and all-cause mortality and did not observe an increased risk of major bleeding, with reloading. The differential profile in the two groups might influence this association and further studies are warranted.